# A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis

> **NCT07675954** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 294 (estimated)

## Conditions studied

- Rifampicin-Resistant Tuberculosis

## Interventions

- **DRUG:** MDR-END Plus regimen
- **DRUG:** Standard-of-care (SoC) treatment

## Key facts

- **NCT ID:** NCT07675954
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2032-06
- **Final completion:** 2032-06
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675954, "A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*